Industry ยท Oct 2026
Diagnostics & Research stocks ranked by gap to the model's fair value
Faircurve's model values 17 diagnostics & research stocks. 15 of them are ranked below by the gap between the model's fair value and the last close, as of 31 Oct 2026: 5 read as Undervalued, 7 as Fairly valued and 3 as Overvalued. The median gap across the ranked names is +4.6%. The widest gaps above the price are IQV (+33.3%), CRL (+27.9%), LH (+21.4%). The widest below it are WAT (-25.7%), ILMN (-19.4%), IDXX (-18.5%).
Valuations as of . Prices are the closes of 3 Nov 2026. The gap is the model's fair value against the price: a positive gap means the fair value is above the price. It states what the model concluded, not where the price goes next.
The ranking
| Rank | Company | Last close | Model fair value | Gap | Model verdict | Quality score | Market value |
|---|---|---|---|---|---|---|---|
| 1 | IQV IQVIA Holdings Inc. | $262.59 | $350.11 | +33.3% | Undervalued | 55 | $44.1B |
| 2 | CRL Charles River Laboratories International, Inc. | $351.87 | $450.20 | +27.9% | Undervalued | 50 | $17.3B |
| 3 | LH Labcorp Holdings Inc. | $353.92 | $429.61 | +21.4% | Undervalued | 54 | $29.3B |
| 4 | DGX Quest Diagnostics Incorporated | $247.06 | $298.39 | +20.8% | Undervalued | 73 | $27.8B |
| 5 | RVTY Revvity, Inc. | $163.48 | $188.77 | +15.5% | Undervalued | 47 | $17.5B |
| 6 | MEDP Medpace Holdings, Inc. | $663.49 | $732.27 | +10.4% | Fairly valued | 82 | $18.2B |
| 7 | NEO NeoGenomics, Inc. | $16.83 | $17.74 | +5.4% | Fairly valued | 42 | $2.3B |
| 8 | A Agilent Technologies, Inc. | $175.46 | $183.45 | +4.6% | Fairly valued | 61 | $49.3B |
| 9 | MTD Mettler-Toledo International Inc. | $1,698.04 | $1,727.57 | +1.7% | Fairly valued | 70 | $33.6B |
| 10 | TMO Thermo Fisher Scientific Inc. | $698.34 | $682.83 | -2.2% | Fairly valued | 52 | $257.7B |
| 11 | RDNT RadNet, Inc. | $73.18 | $69.84 | -4.6% | Fairly valued | 51 | $5.8B |
| 12 | DHR Danaher Corporation | $230.11 | $213.76 | -7.1% | Fairly valued | 41 | $163.3B |
| 13 | IDXX IDEXX Laboratories, Inc. | $672.04 | $547.59 | -18.5% | Overvalued | 79 | $43.4B |
| 14 | ILMN Illumina, Inc. | $238.21 | $191.98 | -19.4% | Overvalued | 52 | $35.6B |
| 15 | WAT Waters Corporation | $459.90 | $341.64 | -25.7% | Overvalued | 48 | $45.4B |
The Global Pulse
Faircurve's market note, in your inbox each market day
The Global Pulse is Faircurve's note after each US session: what moved, in plain words. No account needed.
Valued but not ranked
These 2 names are valued but not ranked, for one of four reasons: the model grades the evidence as low or has not graded it yet, the inputs are under review, the gap is wider than 60%, or the valuation is more than three weeks old. The numbers are shown for reference.
| Company | Last close | Model fair value | Gap | Why it is not ranked | Quality score | Market value |
|---|---|---|---|---|---|---|
| SHC Sotera Health Company | $16.03 | $27.14 | +69.3% | Gap wider than 60% | 55 | $5.2B |
| VCYT Veracyte, Inc. | $50.29 | $50.15 | -0.3% | Low evidence grade | $4.0B |